ACR 2022 | SURPASS: Secukinumab vs adalimumab biosimilar in axSpA | rheumatology.medicinematters.com Skip to main content

23-11-2022 | ACR 2022 | Conference coverage | Video

SURPASS: Secukinumab vs adalimumab biosimilar in axSpA

share
SHARE

Xenofon Baraliakos takes us through SURPASS, a phase 3b head-to-head trial that demonstrated equivalence of secukinumab versus adalimumab biosimilar in patients with radiographic axial spondyloarthritis (4:49).